
DiaMedica Starts Relaunched Phase 2/3 Trial for Acute Stroke Treatment
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for neurological disorders and cardio-renal disease, has disclosed the dosing of the first patient in its relaunched Phase 2/3 ReMEDy2 Trial of DM199 for acute ischemic stroke…












